两种不同化疗方案治疗非小细胞肺癌的最小成本分析  

Cost-minimization analysis of two chemotherapeutic protocols for advanced nonsmall cell lung cancer

作　　者：徐朝江[1] 姜轶飞[2] 孙毅[3] 

机构地区：[1]浙江省嘉兴市第二医院药剂科,嘉兴314000 [2]浙江省嘉兴市第二医院呼吸科,嘉兴314000 [3]浙江大学附属第一医院药剂科,杭州310000

出　　处：《中国临床药学杂志》2014年第1期35-38,共4页Chinese Journal of Clinical Pharmacy

摘　　要：目的对2种非小细胞肺癌(NSCLC)化疗方案(GP、DP方案)进行最小成本分析,为临床化疗方案的选择提供依据。方法回顾分析我院呼吸科和胸外科2010年1月至2012年12月期间收治的NSCLC患者病历81份,分成2组。GP组46份,采用GP方案,即第1、8天予吉西他滨1 000 mg·m-2,iv gtt,第1天予顺铂75 mg·m-2,iv gtt,每3周重复;DP组35份,采用DP方案,即第1天予多西他赛、顺铂各75 mg·m-2,每3周重复。两组方案均以4个周期为一疗程。运用药物经济学的最小成本分析法进行分析。结果 GP、DP组有效率分别为39.1%、37.1%(P>0.05),成本-效果比(C/E有效率)分别为740.39、909.53;DP组相对GP组的增量成本-效果比(ΔC/ΔE)为-2 397,肿瘤控制率分别为82.6%、88.5%(P>0.05)。结论治疗NSCLC,GP方案的经济性较好。AIM To evaluate the cost, clinical efficacy, adverse drug reaction of two chemotherapeutic protocols for advanced non-small cell lung cancer（NSCLC）,to provide a basis for the clinical chemotherapeutic protoeals. METH- ODS By using retrospective study, 81 patients with previously untreated advanced NSCLC were recruited between Jan- uary 2010 and December 2012. Subjects were assigned to the GP team （ n = 46）and the DP team （ n = 35）. GP team： gemcitabine（GEM） 1 000 mg m- 2, iv gtt, d l, d8 ; eisplatin （DDP） 75 mg m- 2, iv gtt, dl ; repeated every 3 weeks. DP team： docetaxel（DOC） 75 mg m- 2, iv gtt, dl ; eisplatin（DDP） 75 mg m- 2, iv gtt, dl ; repeated every 3 weeks. The two teams all took 3 weeks as one cycle,4 cycles as one course of treatment. The study was made by using the cost-minimiza- tion analysis of drugs economics. RESULTS The result indicated that the effective rates were 39.1%, 37.1% （ P 〉 0.05） for GP team and DP team,respectively. The cost effective ratio（C/E the effective rates） were 740.39,909.53, AC/AE were - 2 397, tumor control rates were 82.6 % , 88.5 % , respectively （ P 〉 0.05 ） . CONCLUSION GP team is the preferable chemotherapeutic protocol for advanced non-small cell lung cancer.

关 键 词：非小细胞肺癌 吉西他滨 多西他赛 化疗方案 最小成本分析 

分 类 号：R734.2[医药卫生—肿瘤]